[go: up one dir, main page]

BE2017C056I2 - - Google Patents

Download PDF

Info

Publication number
BE2017C056I2
BE2017C056I2 BE2017C056C BE2017C056C BE2017C056I2 BE 2017C056 I2 BE2017C056 I2 BE 2017C056I2 BE 2017C056 C BE2017C056 C BE 2017C056C BE 2017C056 C BE2017C056 C BE 2017C056C BE 2017C056 I2 BE2017C056 I2 BE 2017C056I2
Authority
BE
Belgium
Application number
BE2017C056C
Original Assignee
Wyeth Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27668840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2017C056(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Holdings Llc filed Critical Wyeth Holdings Llc
Publication of BE2017C056I2 publication Critical patent/BE2017C056I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C12N9/2411—Amylases
    • C12N9/2414—Alpha-amylase (3.2.1.1.)
    • C12N9/2417—Alpha-amylase (3.2.1.1.) from microbiological source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
BE2017C056C 2001-10-11 2017-11-23 BE2017C056I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32810101P 2001-10-11 2001-10-11
US40693402P 2002-08-30 2002-08-30
EP02804818.9A EP1442047B1 (fr) 2001-10-11 2002-10-11 Nouvelle compositions immunogenes utilisees pour la prevention et le traitement de la meningococcie

Publications (1)

Publication Number Publication Date
BE2017C056I2 true BE2017C056I2 (fr) 2022-02-01

Family

ID=27668840

Family Applications (3)

Application Number Title Priority Date Filing Date
BE2017C055C BE2017C055I2 (fr) 2001-10-11 2017-11-23
BE2017C057C BE2017C057I2 (fr) 2001-10-11 2017-11-23
BE2017C056C BE2017C056I2 (fr) 2001-10-11 2017-11-23

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BE2017C055C BE2017C055I2 (fr) 2001-10-11 2017-11-23
BE2017C057C BE2017C057I2 (fr) 2001-10-11 2017-11-23

Country Status (18)

Country Link
US (13) US8101194B2 (fr)
EP (14) EP2341063B1 (fr)
JP (6) JP2005515771A (fr)
KR (4) KR101099916B1 (fr)
CN (4) CN1578785B (fr)
AU (3) AU2009213040C1 (fr)
BE (3) BE2017C055I2 (fr)
BR (1) BRPI0212999B8 (fr)
CA (5) CA2918207C (fr)
DK (10) DK3199539T3 (fr)
ES (14) ES2609039T3 (fr)
FR (4) FR15C0056I2 (fr)
IL (5) IL161052A0 (fr)
LU (4) LU92786I2 (fr)
MX (3) MX339524B (fr)
NL (4) NL300755I2 (fr)
PT (10) PT2348035E (fr)
WO (1) WO2003063766A2 (fr)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001031019A2 (fr) 1999-10-29 2001-05-03 Chiron Spa Peptides antigeniques de neisseria
PT1944371E (pt) 1998-05-01 2015-07-13 Novartis Ag Antigénios e composições da neisseria meningitidis
EP1860191A3 (fr) 1999-05-19 2008-02-13 Novartis Vaccines and Diagnostics S.r.l. Compositions à base de combinaisons de Neisseria
JP2003520248A (ja) 2000-01-17 2003-07-02 カイロン エセ．ピー．アー． Ｎ．ｍｅｎｉｎｇｉｔｉｄｉｓ血清型ｂ外膜タンパク質を含む外膜小胞（ｏｍｖ）ワクチン
EP1790660B1 (fr) 2000-02-28 2012-06-20 Novartis Vaccines and Diagnostics S.r.l. Expression hétérologue de protéines de Neisseria
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP2351579B1 (fr) 2002-10-11 2016-09-21 Novartis Vaccines and Diagnostics S.r.l. Vaccins incluant du NadA oligomère de la méningococcie pour une protection élargie contre des lignées hypervirulentes
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CN101926988B (zh) 2003-01-30 2014-06-04 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
CA2522751A1 (fr) * 2003-04-16 2004-11-04 Wyeth Holdings Corporation Nouvelles compositions immunogenes de prevention de traitement de meningococcie
JP4738339B2 (ja) 2003-10-02 2011-08-03 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 複数の髄膜炎菌血清群についての液体ワクチン
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
CN104815327A (zh) 2005-04-08 2015-08-05 惠氏有限责任公司 多价肺炎球菌多糖-蛋白质缀合物组合物
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
UA95237C2 (uk) 2005-06-27 2011-07-25 Ґлаксосмітклайн Байолоджікалз С.А. Імуногенна композиція
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
AU2013201318B2 (en) * 2005-11-25 2015-11-19 Glaxosmithkline Biologicals Sa Chimeric, hybrid and tandem polypeptides of meningococcal NMB 1870
AU2016204760A1 (en) * 2006-04-26 2016-07-28 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2014268186C1 (en) * 2006-04-26 2017-12-07 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
KR101419958B1 (ko) 2006-07-27 2014-07-16 와이어쓰 엘엘씨 재조합 단백질을 제조하기 위한 고세포 밀도 반회분식 발효방법
AR064642A1 (es) * 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
WO2009104097A2 (fr) 2008-02-21 2009-08-27 Novartis Ag Polypeptides fhbp à méningocoques
JP2012512240A (ja) 2008-12-17 2012-05-31 ノバルティス アーゲー ヘモグロビン受容体を含む髄膜炎菌ワクチン
WO2010109324A1 (fr) 2009-03-24 2010-09-30 Novartis Ag Combinaisons de protéine liant le facteur h de méningocoque et de conjugués de saccharide de pneumocoque
NZ595234A (en) 2009-03-24 2013-12-20 Novartis Ag Adjuvanting meningococcal factor h binding protein
WO2011008400A2 (fr) 2009-06-16 2011-01-20 Novartis Ag Dosages haut débit de bactéricides opsoniques et dépendant d'anticorps à médiation par le complément
US8858958B2 (en) 2009-08-27 2014-10-14 Novartis Ag Adjuvant comprising aluminum, oligonucleotide and polycation
EP2470204B1 (fr) 2009-08-27 2015-12-16 GlaxoSmithKline Biologicals SA Polypeptides hybrides contenant des séquences fhbp à méningocoques
AU2010302344A1 (en) 2009-09-30 2012-04-26 Novartis Ag Expression of meningococcal fhbp polypeptides
CN102917730A (zh) 2009-10-27 2013-02-06 诺华有限公司 修饰的脑膜炎球菌fHBP多肽
ES2661569T3 (es) 2010-03-30 2018-04-02 Children's Hospital & Research Center At Oakland Proteínas de unión al factor H (fHbp) con propiedades alteradas y métodos de uso de las mismas
DK2575870T3 (en) 2010-06-04 2017-02-13 Wyeth Llc vaccine Formulations
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
MX350142B (es) * 2010-08-23 2017-08-28 Wyeth Llc * Formulaciones estables de antigenos rlp2086 de neisseria meningitidis.
SG187912A1 (en) 2010-09-10 2013-04-30 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
GB201015132D0 (en) * 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
US9259462B2 (en) 2010-09-10 2016-02-16 Glaxosmithkline Biologicals Sa Developments in meningococcal outer membrane vesicles
CA2828844C (fr) 2011-03-02 2020-07-14 Novartis Ag Vaccins combines comprenant des doses inferieures d'antigene et/ou d'adjuvant
US20150147356A1 (en) 2011-05-12 2015-05-28 Alan Kimura Antipyretics to enhance tolerability of vesicle-based vaccines
BR112014016223A8 (pt) * 2011-12-29 2017-07-04 Novartis Ag combinações adjuvantes de proteínas de ligação de fator h meningocócico
WO2013113917A1 (fr) 2012-02-02 2013-08-08 Novartis Ag Promoteurs pour une expression protéique accrue dans les méningocoques
CN104159603A (zh) 2012-03-08 2014-11-19 诺华股份有限公司 带有tlr4激动剂的联合疫苗
WO2013132040A2 (fr) 2012-03-08 2013-09-12 Novartis Ag Dosage de puissance in vitro pour des vaccins méningococciques à base de protéine
KR101763625B1 (ko) 2012-03-09 2017-08-01 화이자 인코포레이티드 수막염균 조성물 및 이의 사용 방법
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
JP2015521595A (ja) 2012-06-14 2015-07-30 ノバルティス アーゲー 血清群ｘ髄膜炎菌のためのワクチン
US10000545B2 (en) 2012-07-27 2018-06-19 Institut National De La Sante Et De La Recherche Medicale CD147 as receptor for pilus-mediated adhesion of Meningococci to vascular endothelia
EP2892553A1 (fr) 2012-09-06 2015-07-15 Novartis AG Vaccins combinatoires avec méningococcus de sérogroupe b et d/t/p
WO2014136064A2 (fr) 2013-03-08 2014-09-12 Pfizer Inc. Polypeptides immunogènes de fusion
KR20160034401A (ko) 2013-08-02 2016-03-29 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 비-천연적으로 발생하는 인자 h 결합 단백질(fhbp) 및 이의 사용 방법
CA2923129C (fr) * 2013-09-08 2020-06-09 Pfizer Inc. Compositions utilisables contre neisseria meningitidis et procedes associes
MX373277B (es) 2014-02-28 2020-05-20 Glaxosmithkline Biologicals Sa Polipeptidos fhbp meningococicos modificados.
CN106715464B (zh) 2014-07-23 2021-03-16 奥克兰儿童医院及研究中心 因子h结合蛋白变体及其使用方法
US11031102B2 (en) 2014-11-17 2021-06-08 Alexion Pharmaceuticals, Inc. Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
EP3263695A1 (fr) 2016-06-29 2018-01-03 GlaxoSmithKline Biologicals SA Compositions immunogènes
CN106434720A (zh) * 2016-08-03 2017-02-22 中国医学科学院医学生物学研究所 提高脑膜炎奈瑟菌fHBP蛋白表达的方法
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
PL3506935T3 (pl) 2016-09-02 2024-06-10 Sanofi Pasteur, Inc. Szczepionka przeciwko Neisseria meningitidis
WO2018042015A1 (fr) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccins contre neisseria gonorrhoeae
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
CN111316161B (zh) * 2017-09-28 2021-11-23 富士胶片株式会社 摄像装置、信息获取方法及信息获取程序
WO2019065555A1 (fr) 2017-09-28 2019-04-04 富士フイルム株式会社 Dispositif de capture d'images, procédé d'acquisition d'informations et programme d'acquisition d'informations
TWI687696B (zh) * 2019-06-26 2020-03-11 國立中興大學 回饋型隱藏式馬可夫模型辨識器的建立方法與基於此辨識器的辨識系統的建立方法
CA3155669A1 (fr) 2019-09-27 2021-04-01 Pfizer Inc. Compositions de neisseria meningitidis et methodes associees
CN114681601B (zh) * 2020-12-31 2025-08-19 基础治疗有限公司 脑膜炎奈瑟氏球菌疫苗及其应用
WO2022178196A1 (fr) * 2021-02-19 2022-08-25 Sanofi Pasteur Inc. Vaccin recombinant méningococcique b
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
EP4468950A1 (fr) 2022-01-24 2024-12-04 Koninklijke Philips N.V. Détermination de vitesse d'onde de pouls par co-enregistrement de données intravasculaires et d'une image extraluminale, et systèmes, dispositifs et procédés associés
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物
WO2025199107A1 (fr) 2024-03-19 2025-09-25 Alexion Pharmaceuticals, Inc. Stratégie d'évaluation et de gestion des risques impliquant un suivi des patients dans le cadre de l'utilisation ou de l'interruption d'un inhibiteur du complément
CN120227449A (zh) * 2025-05-21 2025-07-01 苏州聚微生物科技有限公司 B群脑膜炎球菌疫苗组合物及其制备方法与应用
CN120241991B (zh) * 2025-06-05 2025-12-23 北京绿竹生物技术股份有限公司 一种新型的b群流脑外膜蛋白双功能载体

Family Cites Families (248)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT280356B (de) 1968-03-06 1970-04-10 Telefonbau & Normalzeit Gmbh Schaltungsanordnung zur Steuerung des zur Zwischenspeicherung des Zeitwertes eines Signales verwendeten Kondensators eines Demodulators einer Zeitmultiplexanlage
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
CH660375A5 (it) * 1983-02-08 1987-04-15 Sclavo Spa Procedimento per la produzione di proteine correlate alla tossina difterica.
EP0138854B1 (fr) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Sequences d'acides amines antigeniquement actives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4668829A (en) * 1984-07-18 1987-05-26 University Patents, Inc. Ferroelectric smectic liquid crystals
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8424757D0 (en) 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
WO1987001130A1 (fr) 1985-08-15 1987-02-26 Stauffer Chemical Company Microorganisme producteur de tryptophane
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
WO1987002671A1 (fr) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Assemblage modulaire de genes d'anticorps, anticorps ainsi prepares et utilisation
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5514581A (en) * 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
JPH01125328A (ja) 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
JPH01144977A (ja) 1987-11-30 1989-06-07 Agency Of Ind Science & Technol 新規組換えプラスミドｐＴＰＧＩＦ２
WO1989007150A1 (fr) 1988-02-05 1989-08-10 The Trustees Of Columbia University In The City Of Lignees de cellules de conservation de retrovirus et leurs procedes d'utilisation
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JP3082204B2 (ja) 1988-09-01 2000-08-28 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス
US7118757B1 (en) * 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
EP0606921B1 (fr) 1989-03-09 2000-08-02 American Cyanamid Company Procédé pour isoler la protéine-E d'hémophilus influenzae
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2039921A1 (fr) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfert et expression de la sequence d'adn dans les cellules du systeme nerveux central a l'aide de mutants du virus de l'herpes, avec deletions chez les genes en vue de repliquer le virus
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991018088A1 (fr) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Vecteurs eucaryotiques a base de virus adeno-associes (aav)
IE912559A1 (en) 1990-07-19 1992-01-29 Merck & Co Inc The class ii protein of the outer membrane of neisseria¹meningitidis, and vaccines containing same
JPH0453645U (fr) * 1990-09-12 1992-05-07
KR100372934B1 (ko) 1990-09-25 2003-12-24 캔탑 파마슈티칼스 리서취 리미티드 형질 상보성 세포주에 의해 생성된 바이러스 결손 백신
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
EP0625052A4 (fr) 1991-10-21 1995-07-19 Medimmune Inc Vecteurs d'expression bacteriens contenant de l'adn codant des signaux de secretion de lipoproteines.
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
WO1993015115A1 (fr) * 1992-01-24 1993-08-05 Cornell Research Foundation, Inc. HOLOENZYME ADN POLYMERASE III et E. COLI ET SOUS-UNITES
EP1024198A3 (fr) 1992-12-03 2002-05-29 Genzyme Corporation Vecteurs pseudo-adenoviraux pour la thérapie génique des hémophilies
PT616034E (pt) * 1993-03-05 2005-02-28 Wyeth Corp Plasmideo para a producao de proteina crm e toxina da difteria
WO1994021807A2 (fr) 1993-03-19 1994-09-29 Cantab Pharmaceuticals Research Limited Virus mutant defectueux non retroviral (par ex. hsv) utilise comme vaccin
DK0624376T3 (da) 1993-05-13 2000-07-24 American Cyanamid Co Fremstilling og anvendelse af LOS-udtømte ydre membranproteiner af gram-negative cocci
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
KR100356615B1 (ko) 1993-07-13 2003-04-03 아방티 파르마 소시에테 아노님 결함아데노바이러스벡터및유전자치료에서그의사용
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
JPH09501055A (ja) 1993-07-30 1997-02-04 ユニバーシティ オブ メディシン アンド デンティストリー オブ ニュージャージー 初代リンパ球への効率的遺伝子転移
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
US5550213A (en) * 1993-12-27 1996-08-27 Rutgers, The State University Of New Jersey Inhibitors of urokinase plasminogen activator
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FI98045C (fi) 1994-02-21 1997-04-10 Arto Remes Laite inkontinenssihoitoa varten
FR2716459B1 (fr) 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
AU2194895A (en) 1994-03-25 1995-10-17 Uab Research Foundation, The Composition and methods for creating syngeneic recombinant virus-producing cells
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
CA2187818A1 (fr) 1994-04-15 1995-10-26 Robert W. Overell Proteine de fusion d'apport de gene
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
AU2356095A (en) * 1994-04-20 1995-11-29 U.S. Department Of The Army Vaccine against gram-negative bacterial infections
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
WO1996039036A1 (fr) 1995-06-05 1996-12-12 The University Of Alabama At Birmingham Research Foundation Procedes et composition de creation de cellules syngeniques productrices de virus recombines
IL118578A (en) * 1995-06-07 2006-12-31 Connaught Lab Hybrid nucleic acid molecule for expression of lipoproteins
FR2741358B1 (fr) 1995-11-17 1998-01-02 Centre Nat Rech Scient Production de vecteurs retroviraux par l'intermediaire de vecteurs viraux a base de virus a adn
CU22559A1 (es) * 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6355255B1 (en) * 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
WO1998008874A1 (fr) 1996-08-27 1998-03-05 Chiron Corporation Anticorps monoclonaux definissant des epitopes meningococciques b et leurs utilisations dans la preparation de compositions vaccinales
DE69708318T3 (de) 1996-08-27 2006-11-16 Novartis Vaccines and Diagnostics, Inc., Emeryville Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
AU5426098A (en) 1996-10-24 1998-05-15 Emory University Invasion associated genes from (neisseria meningitidis) serogroup
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
DE19723095C2 (de) * 1997-06-02 2001-08-23 Siemens Ag Bildrekonstruktionsverfahren für einen Computertomographen
IL133708A0 (en) 1997-06-30 2001-04-30 Rhone Poulence Rorer S A Improved method for transferring nucleic acid into multicelled eukaryotic organism cells and combination thereof
BR9810500A (pt) 1997-06-30 2000-09-05 Rhone Poulenc Rorer Sa Sistema e aparelho para a transferência de ácido nucléico in vivo para o interior de células de organismos eucarióticos pluricelulares
IL133710A0 (en) 1997-06-30 2001-04-30 Rhone Poulence Rorer S A Improved method for transferring nucleic acid into the striped muscle and combination thereof
KR20010021953A (ko) * 1997-07-17 2001-03-15 추후제출 Ｂ군 수막염균 포린 및 에이치.인플루엔자 다당류를포함하는 면역원성 접합체
JPH1144977A (ja) 1997-07-25 1999-02-16 Copyer Co Ltd 画像形成装置
AU9120898A (en) 1997-08-27 1999-03-16 Chiron Corporation Molecular mimetics of meningococcal b epitopes
AU753943B2 (en) * 1997-08-29 2002-10-31 Dow Global Technologies Inc. Homogeneous filled polymer composite
AU9363798A (en) 1997-11-06 1999-05-31 Chiron S.P.A. Neisserial antigens
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
CA2317815A1 (fr) 1998-01-14 1999-07-22 Chiron S.P.A. Antigenes du $i(neisseria meningitidis)
WO1999040200A1 (fr) * 1998-02-03 1999-08-12 Center For Disease Control And Prevention PROTEINE PsaA RECOMBINEE LIPIDEE, METHODES DE PREPARATION ET D'UTILISATION
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
GB9808734D0 (en) 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
PT1944371E (pt) 1998-05-01 2015-07-13 Novartis Ag Antigénios e composições da neisseria meningitidis
WO2001031019A2 (fr) 1999-10-29 2001-05-03 Chiron Spa Peptides antigeniques de neisseria
JP5074644B2 (ja) 1998-05-29 2012-11-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 組合わせの髄膜炎菌ｂ／ｃワクチン
MXPA01003228A (es) 1998-09-30 2003-06-24 American Cyanamid Co Holotoxina de colera mutante como un coadyuvante.
WO2000018355A2 (fr) * 1998-09-30 2000-04-06 Walter Reed Army Institute Of Research Utilisation en tant que vaccin d'invaplex purifie obtenu a partir de bacteries a gram negatif
CA2346713A1 (fr) 1998-10-09 2000-04-20 Chiron Corporation Sequences genomiques de neisseria et procedes d'utilisation
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6281337B1 (en) 1998-11-12 2001-08-28 Schering Corporation Methods for conversion of protein isoforms
EP1144645A1 (fr) 1999-01-15 2001-10-17 SMITHKLINE BEECHAM BIOLOGICALS s.a. Polypeptides basb052 de (neisseria meningitidis)
CA2360658A1 (fr) 1999-01-22 2000-07-27 Smithkline Beecham Biologicals S.A. Polypeptides antigeniques de neisseria meningitidis, polynucleotides correspondants et anticorps protecteurs
GB9902084D0 (en) * 1999-01-29 1999-03-24 Smithkline Beecham Biolog Novel compounds
DE60040727D1 (de) 1999-02-05 2008-12-18 Merck & Co Inc Menschliche papillomavirus impfstoff-formulierungen
ATE279943T1 (de) 1999-02-26 2004-11-15 Chiron Srl Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
CA2371032A1 (fr) 1999-04-30 2000-11-09 Chiron Corporation Sequences genomiques de neisseria et procedes d'utilisation correspondants
EP2290083B1 (fr) 1999-04-30 2014-08-20 Novartis Vaccines and Diagnostics S.r.l. Antigènes conservés de Neisseria
EP1860191A3 (fr) * 1999-05-19 2008-02-13 Novartis Vaccines and Diagnostics S.r.l. Compositions à base de combinaisons de Neisseria
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
AU1875301A (en) 1999-11-29 2001-06-04 Chiron S.P.A. 85kda neisserial antigen
CA2393298C (fr) 1999-12-02 2011-02-01 Chiron Corporation Compositions et procedes de stabilisation de molecules biologiques lors dune operation de lyophilisation
JP2003520248A (ja) * 2000-01-17 2003-07-02 カイロン エセ．ピー．アー． Ｎ．ｍｅｎｉｎｇｉｔｉｄｉｓ血清型ｂ外膜タンパク質を含む外膜小胞（ｏｍｖ）ワクチン
EP1790660B1 (fr) * 2000-02-28 2012-06-20 Novartis Vaccines and Diagnostics S.r.l. Expression hétérologue de protéines de Neisseria
HU228264B1 (en) 2000-06-08 2013-02-28 Intercell Ag Immunostimulatory oligodeoxynucleotides
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
KR100947757B1 (ko) 2001-01-23 2010-03-18 아벤티스 파스퇴르 다가 수막구균 폴리사카라이드―단백질 접합체 백신
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
CA2441327A1 (fr) 2001-03-30 2002-10-10 Geneprot, Inc. Compositions proteiques humaines riches en arginine-
WO2002083710A2 (fr) 2001-04-13 2002-10-24 Wyeth Holdings Corporation Elimination d'endotoxine bacterienne dans une solution proteique par chromatographie d'affinite metallique immobilisee
CN1306956C (zh) 2001-04-17 2007-03-28 希龙公司 诱导功能活性抗体的脑膜炎球菌b抗原表位的分子模拟物
CA2449670A1 (fr) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Formes mutantes de l'holotoxine du cholera utilisees comme adjuvant
EP1404368B1 (fr) 2001-06-07 2009-12-09 Wyeth Holdings Corporation Formes mutantes de l'holotoxine du cholera en tant qu'adjuvant
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
WO2003009869A1 (fr) 2001-07-26 2003-02-06 Chiron Srl. Vaccins comprenant des adjuvants aluminium et histidine
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
CA2460546A1 (fr) * 2001-09-14 2003-03-27 Invitrogen Corporation Adn polymerases et mutants correspondants
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0129007D0 (en) 2001-12-04 2002-01-23 Chiron Spa Adjuvanted antigenic meningococcal compositions
NZ535968A (en) 2002-03-26 2006-08-31 Chiron S Modified saccharides having improved stability in water
DE60328481D1 (de) 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
MXPA04011248A (es) 2002-05-14 2005-02-17 Chiron Srl Vacunas mucosales en combinacion para la meningitis bacteriana.
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0220198D0 (en) 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
EP2351579B1 (fr) 2002-10-11 2016-09-21 Novartis Vaccines and Diagnostics S.r.l. Vaccins incluant du NadA oligomère de la méningococcie pour une protection élargie contre des lignées hypervirulentes
US20070059329A1 (en) 2002-11-15 2007-03-15 Nathalie Norais Unexpected surface proteins in meningococcus
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
WO2004065603A2 (fr) 2003-01-15 2004-08-05 Wyeth Holdings Corporation Methodes d'augmentation de l'expression de la proteine neisseria et compositions associees
CN101926988B (zh) 2003-01-30 2014-06-04 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
CA2519511A1 (fr) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Holotoxine du cholera mutante en tant qu'adjuvant et proteine de support d'antigene
CA2522751A1 (fr) 2003-04-16 2004-11-04 Wyeth Holdings Corporation Nouvelles compositions immunogenes de prevention de traitement de meningococcie
ES2328697T5 (es) 2003-06-02 2017-07-25 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunogénicas basadas en micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
US20050019337A1 (en) 2003-06-23 2005-01-27 Ryall Robert P. Immunization method against Neisseria meningitidis serogroups A and C
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
JP4738339B2 (ja) 2003-10-02 2011-08-03 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 複数の髄膜炎菌血清群についての液体ワクチン
AU2004312067A1 (en) 2003-12-30 2005-07-21 Wyeth Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0408978D0 (en) 2004-04-22 2004-05-26 Chiron Srl Meningococcal fermentation for preparing conjugate vaccines
NZ550533A (en) 2004-04-30 2010-02-26 Novartis Vaccines & Diagnostic Meningococcal conjugate vaccination comprising N. meningitidis and diphtheria toxin
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
CA2574375C (fr) 2004-07-23 2015-03-17 Chiron Srl Polypeptides pour assemblage oligomere d'antigenes
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419846D0 (en) 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
CN101107007B (zh) * 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
WO2006096701A2 (fr) 2005-03-07 2006-09-14 Id Biomedical Corporation Of Quebec C.O.B. As Glaxosmithkline Biologicals North America Compositions pharmaceutiques liposomales
ES2533248T3 (es) 2005-05-06 2015-04-08 Novartis Ag Inmunógenos para vacunas contra Meningitidis A
UA95237C2 (uk) 2005-06-27 2011-07-25 Ґлаксосмітклайн Байолоджікалз С.А. Імуногенна композиція
EP2308505A3 (fr) 2005-09-01 2011-11-30 Novartis Vaccines and Diagnostics GmbH Vaccins multiples comprenant le sérogroupe C de Neisseria meningitidis
CA2621578C (fr) 2005-09-05 2014-07-22 Glaxosmithkline Biologicals S.A. Essai d'activite bactericide serique pour des antiserums specifiques de n. meningitidis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
BRPI0620418A2 (pt) 2005-12-23 2011-11-08 Glaxosmithkline Biolog Sa método para imunizar um paciente humano contra uma doença, usos de pelo menos dois e de pelo menos sete, dez, onze, treze ou quatorze conjugados e das vacinas, e, kit
DK2004225T3 (da) 2006-03-22 2012-08-06 Novartis Ag Programmer for vaccination med meningocockonjugater
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
WO2007127668A2 (fr) 2006-04-26 2007-11-08 Wyeth Nouveaux procedes de revetement d'un contenant empechant la precipitation de formulations de conjugues de polysaccharide-proteine
EP2032161B1 (fr) 2006-06-12 2012-07-11 GlaxoSmithKline Biologicals S.A. Vaccins l3v los
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
MX2008016280A (es) * 2006-06-29 2009-03-26 Novartis Ag Polipeptidos a partir de neisseria meningitidis.
KR101419958B1 (ko) 2006-07-27 2014-07-16 와이어쓰 엘엘씨 재조합 단백질을 제조하기 위한 고세포 밀도 반회분식 발효방법
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
JP5637848B2 (ja) 2007-06-04 2014-12-10 ノバルティス アーゲー 髄膜炎ワクチンの製剤化
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2185576A4 (fr) * 2007-08-02 2011-01-12 Childrens Hosp & Res Ct Oak Vaccins vésiculaires à base de fhbp et de lpxl1 pour une protection à large spectre contre les maladies à neisseria meningitidis
ATE553774T1 (de) 2007-10-19 2012-05-15 Novartis Ag Meningokokkenimpfstoffformulierungen
WO2009104097A2 (fr) 2008-02-21 2009-08-27 Novartis Ag Polypeptides fhbp à méningocoques
WO2009109550A1 (fr) 2008-03-05 2009-09-11 Sanofi Pasteur Procédé de stabilisation d’un adjuvant contenant une composition de vaccin
AU2009223613B2 (en) * 2008-03-10 2014-09-25 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
EP2297578A2 (fr) 2008-05-19 2011-03-23 Novartis AG Essais de vaccin
KR20110053314A (ko) 2008-05-30 2011-05-20 더 유에스에이, 애즈 리프리젠티드 바이 더 세크리터리 오브 더 아미, 온 비하프 오브 월터 리드 아미 수막구균성 다가 천연 외막 소포체 백신, 이의 제조 방법 및 사용 방법
BRPI0917306A2 (pt) 2008-08-27 2016-04-19 Childrens Hosp & Res Ct Oak ensaios com base fator de complemento h para a atividade sérica bacterecida contra neisseria meningitidis
CA2733943A1 (fr) 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presentant un epitope d'un domaine a de proteine de liaison au facteur h et procedes d'utilisation
IT1394288B1 (it) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
US9393304B2 (en) 2008-10-29 2016-07-19 Ablynx N.V. Formulations of single domain antigen binding molecules
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
JP5410084B2 (ja) * 2008-12-15 2014-02-05 川上産業株式会社 梱包箱及び箱状芯材
JP2012512240A (ja) 2008-12-17 2012-05-31 ノバルティス アーゲー ヘモグロビン受容体を含む髄膜炎菌ワクチン
WO2010109324A1 (fr) 2009-03-24 2010-09-30 Novartis Ag Combinaisons de protéine liant le facteur h de méningocoque et de conjugués de saccharide de pneumocoque
NZ595234A (en) * 2009-03-24 2013-12-20 Novartis Ag Adjuvanting meningococcal factor h binding protein
EP2424563A4 (fr) 2009-04-30 2013-10-30 Childrens Hosp & Res Ct Oak Protéines de liaison à facteur h chimérique (fhbp) et procédés d'utilisation
US9365885B2 (en) 2009-06-16 2016-06-14 Puiying Annie Mak High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
EP2470204B1 (fr) 2009-08-27 2015-12-16 GlaxoSmithKline Biologicals SA Polypeptides hybrides contenant des séquences fhbp à méningocoques
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
AU2010302344A1 (en) 2009-09-30 2012-04-26 Novartis Ag Expression of meningococcal fhbp polypeptides
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
JP3158225U (ja) * 2009-10-22 2010-03-25 王　文燦 折畳める物置袋
CN102917730A (zh) 2009-10-27 2013-02-06 诺华有限公司 修饰的脑膜炎球菌fHBP多肽
WO2011080595A2 (fr) 2009-12-30 2011-07-07 Novartis Ag Immunogènes de polysaccharide conjugués à des protéines porteuses de e. coli
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
JP2013521770A (ja) 2010-03-10 2013-06-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物
MX2012010609A (es) 2010-03-18 2012-10-03 Novartis Ag Vacunas adyuvadas para meningococos serogrupo b.
ES2661569T3 (es) 2010-03-30 2018-04-02 Children's Hospital & Research Center At Oakland Proteínas de unión al factor H (fHbp) con propiedades alteradas y métodos de uso de las mismas
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
MX350142B (es) 2010-08-23 2017-08-28 Wyeth Llc * Formulaciones estables de antigenos rlp2086 de neisseria meningitidis.
WO2012031271A1 (fr) 2010-09-04 2012-03-08 Novartis Ag Dosages d'anticorps bactéricides pour évaluer l'immunogénicité et la puissance de vaccins contre le méningocoque constitués de saccharides capsulaires
SG187912A1 (en) 2010-09-10 2013-04-30 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
US20120070457A1 (en) 2010-09-10 2012-03-22 J. Craig Venter Institute, Inc. Polypeptides from neisseria meningitidis
US9259462B2 (en) 2010-09-10 2016-02-16 Glaxosmithkline Biologicals Sa Developments in meningococcal outer membrane vesicles
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
CA2828844C (fr) 2011-03-02 2020-07-14 Novartis Ag Vaccins combines comprenant des doses inferieures d'antigene et/ou d'adjuvant
WO2012134975A1 (fr) 2011-03-28 2012-10-04 St. Jude Children's Research Hospital Méthodes et compositions utilisant des protéines de fusion immunogènes
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
KR101763625B1 (ko) 2012-03-09 2017-08-01 화이자 인코포레이티드 수막염균 조성물 및 이의 사용 방법
WO2014136064A2 (fr) 2013-03-08 2014-09-12 Pfizer Inc. Polypeptides immunogènes de fusion
US9965924B2 (en) 2013-07-15 2018-05-08 Ahmnon D. Moskowitz Methods, systems, and apparatus for playing multi-zone 21
CA2923129C (fr) 2013-09-08 2020-06-09 Pfizer Inc. Compositions utilisables contre neisseria meningitidis et procedes associes
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos

Also Published As

Publication number Publication date
CA2463476A1 (fr) 2003-08-07
CN102836426B (zh) 2016-09-28
FR17C1044I1 (fr) 2017-12-22
US20120308595A1 (en) 2012-12-06
EP2348034B1 (fr) 2016-11-02
CA2849427C (fr) 2016-10-04
EP2343308A2 (fr) 2011-07-13
EP2351767A2 (fr) 2011-08-03
US9757444B2 (en) 2017-09-12
ES2562811T3 (es) 2016-03-08
EP2348034A3 (fr) 2011-09-21
EP3199539B1 (fr) 2020-03-11
EP2343308B1 (fr) 2015-02-18
EP2348035A2 (fr) 2011-07-27
EP2371837B1 (fr) 2016-09-21
KR20110117726A (ko) 2011-10-27
US20150216960A1 (en) 2015-08-06
CN102836426A (zh) 2012-12-26
DK2371838T3 (en) 2016-02-22
ES2625876T3 (es) 2017-07-20
AU2012202916B2 (en) 2013-08-01
FR15C0056I2 (fr) 2016-06-03
PT2332961T (pt) 2016-09-28
NL300755I2 (nl) 2025-11-25
EP2332961A2 (fr) 2011-06-15
CN1578785A (zh) 2005-02-09
JP5404441B2 (ja) 2014-01-29
DK2348035T3 (en) 2015-04-20
ES2615206T3 (es) 2017-06-05
IL161052A0 (en) 2004-08-31
CA2918207C (fr) 2016-10-18
BRPI0212999B8 (pt) 2021-07-27
US9168293B2 (en) 2015-10-27
PT2348036E (pt) 2016-03-09
US20120201844A1 (en) 2012-08-09
EP2348035B1 (fr) 2015-02-18
DK2348036T3 (en) 2016-02-22
IL245955A0 (en) 2016-07-31
LUC00041I2 (fr) 2017-12-20
EP2332961A3 (fr) 2011-07-27
CA2939781C (fr) 2022-09-13
KR20040066793A (ko) 2004-07-27
EP2371836B1 (fr) 2016-12-14
NL300899I2 (nl) 2018-04-06
EP2348036A2 (fr) 2011-07-27
FR17C1042I2 (fr) 2018-12-07
NL300899I1 (nl) 2017-10-20
EP2343308A3 (fr) 2011-07-27
JP5923070B2 (ja) 2016-05-24
DK2343308T3 (en) 2015-03-30
EP2371838A1 (fr) 2011-10-05
EP2341063B1 (fr) 2015-08-26
KR20100028657A (ko) 2010-03-12
US8563006B2 (en) 2013-10-22
US20120294880A1 (en) 2012-11-22
US8563007B1 (en) 2013-10-22
CA2894296A1 (fr) 2003-08-07
EP1442047A2 (fr) 2004-08-04
DK2351767T3 (en) 2015-10-26
HK1178429A1 (zh) 2013-09-13
EP3199539A1 (fr) 2017-08-02
AU2012202916A1 (en) 2012-06-07
JP2005515771A (ja) 2005-06-02
CA2894296C (fr) 2018-05-01
ES2568895T3 (es) 2016-05-05
US20120301496A1 (en) 2012-11-29
EP2351767A3 (fr) 2011-09-14
PT2371836T (pt) 2017-02-17
LUC00040I1 (fr) 2017-10-16
US10300122B2 (en) 2019-05-28
ES2609039T3 (es) 2017-04-18
CA2918207A1 (fr) 2003-08-07
ES2532640T3 (es) 2015-03-30
PT2348035E (pt) 2015-03-25
LUC00042I1 (fr) 2017-10-16
CN102755631B (zh) 2015-11-25
DK2332961T3 (en) 2016-10-03
KR101099916B1 (ko) 2011-12-28
DK2341063T3 (en) 2015-10-26
BRPI0212999B1 (pt) 2020-04-28
WO2003063766A2 (fr) 2003-08-07
DK3199539T3 (da) 2020-04-27
LUC00040I2 (fr) 2017-12-20
JP2015214545A (ja) 2015-12-03
EP2371836A1 (fr) 2011-10-05
NL300897I2 (nl) 2018-04-06
MXPA04003356A (es) 2004-11-29
BE2017C057I2 (fr) 2022-02-01
MX349481B (es) 2017-07-31
LU92786I2 (fr) 2015-11-02
AU2012202916C1 (en) 2017-06-08
JP2010162023A (ja) 2010-07-29
ES2549764T3 (es) 2015-11-02
US20130259889A1 (en) 2013-10-03
EP2341063A2 (fr) 2011-07-06
FR17C1043I2 (fr) 2018-12-07
ES2561430T3 (es) 2016-02-26
ES2603532T3 (es) 2017-02-28
KR101068318B1 (ko) 2011-09-28
KR101215664B1 (ko) 2012-12-26
US9107873B2 (en) 2015-08-18
ES2532639T3 (es) 2015-03-30
US20120034261A1 (en) 2012-02-09
CA2849427A1 (fr) 2003-08-07
US20060257413A1 (en) 2006-11-16
US9623101B2 (en) 2017-04-18
PT3199539T (pt) 2020-04-01
ES2781213T3 (es) 2020-08-31
IL245956B (en) 2019-02-28
LUC00042I2 (fr) 2017-12-20
PT2341063E (pt) 2015-10-29
AU2009213040C1 (en) 2012-10-11
EP2341062A3 (fr) 2011-09-14
FR17C1044I2 (fr) 2018-12-07
EP2341062A2 (fr) 2011-07-06
EP2348035A3 (fr) 2011-09-14
CN102755631A (zh) 2012-10-31
PT2371838E (pt) 2016-03-23
US20190151431A1 (en) 2019-05-23
ES2603531T3 (es) 2017-02-28
ES2593360T3 (es) 2016-12-07
FR17C1042I1 (fr) 2017-12-22
WO2003063766A3 (fr) 2004-01-08
AU2009213040B2 (en) 2012-03-01
FR17C1043I1 (fr) 2017-12-22
EP2341063A3 (fr) 2011-09-14
JP2017025061A (ja) 2017-02-02
DK2341062T3 (en) 2017-05-08
DK2371836T3 (en) 2017-02-20
EP2351767B1 (fr) 2015-08-26
IL233545A0 (en) 2014-08-31
IL233545A (en) 2017-10-31
HK1178800A1 (zh) 2013-09-19
PT2341062T (pt) 2017-06-02
US20110076299A1 (en) 2011-03-31
JP2016165275A (ja) 2016-09-15
PT2351767E (pt) 2015-10-30
BE2017C055I2 (fr) 2022-02-01
PT2343308E (pt) 2015-03-25
NL300896I2 (nl) 2018-04-06
US8101194B2 (en) 2012-01-24
IL245955B (en) 2018-01-31
EP2348036B1 (fr) 2015-12-16
IL245956A0 (en) 2016-07-31
EP2371837A1 (fr) 2011-10-05
CA2463476C (fr) 2017-09-12
EP1442047A4 (fr) 2005-06-01
US20150335724A1 (en) 2015-11-26
US20200138933A1 (en) 2020-05-07
MX339524B (es) 2016-05-30
EP2332961B1 (fr) 2016-07-27
IL161052A (en) 2015-04-30
US20170173140A1 (en) 2017-06-22
US11116829B2 (en) 2021-09-14
EP2366707B1 (fr) 2016-09-21
AU2009213040A1 (en) 2009-10-08
EP1442047B1 (fr) 2016-03-16
EP2371838B1 (fr) 2015-12-16
EP2348036A3 (fr) 2011-08-03
EP2366707A1 (fr) 2011-09-21
JP5997400B2 (ja) 2016-09-28
CN105617372A (zh) 2016-06-01
BR0212999A (pt) 2006-05-23
CA2939781A1 (fr) 2003-08-07
JP2014012002A (ja) 2014-01-23
ES2549765T3 (es) 2015-11-02
JP5976880B2 (ja) 2016-08-24
US9132182B2 (en) 2015-09-15
CN1578785B (zh) 2013-03-13
EP2348034A2 (fr) 2011-07-27
KR20100121699A (ko) 2010-11-18
NL300896I1 (nl) 2017-10-20
NL300897I1 (nl) 2017-10-20
FR15C0056I1 (fr) 2015-09-11
EP2341062B1 (fr) 2017-03-29
AU2018203627A1 (en) 2018-06-07
LUC00041I1 (fr) 2017-10-16

Similar Documents

Publication Publication Date Title
BE2017C057I2 (fr)
BE2015C077I2 (fr)
BE2015C046I2 (fr)
BE2014C036I2 (fr)
BE2014C026I2 (fr)
BE2014C004I2 (fr)
BE2012C022I2 (fr)
BE2007C047I2 (fr)
JP2001292394A5 (fr)
JP2002164181A5 (fr)
BE2014C006I2 (fr)
BRPI0209186B1 (fr)
BRPI0204884B1 (fr)
JP2002233529A5 (fr)
CH1379220H1 (fr)
BE2014C008I2 (fr)
JP2002203211A5 (fr)
JP2002192910A5 (fr)
BRPI0210463A2 (fr)
JP2001290171A5 (fr)
JP2002247290A5 (fr)
AU2000280389A8 (fr)
JP2002142688A5 (fr)
JP2001313853A5 (fr)
JP2002074439A5 (fr)